|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.94 USD | -1.13% |
|
-10.96% | -25.94% |
| 02-13 | Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US | FW |
| 02-13 | Novo's Wegovy pill tracks over 38,000 prescriptions in fifth week | RE |
| Capitalization | 28.31B 23.86B 21.76B 20.77B 38.56B 2,564B 40.07B 253B 100B 1,238B 106B 104B 4,328B | P/E ratio 2025 |
28.8x | P/E ratio 2026 * | 19.9x |
|---|---|---|---|---|---|
| Enterprise value | 41.66B 35.1B 32.02B 30.57B 56.74B 3,773B 58.95B 372B 148B 1,822B 156B 153B 6,368B | EV / Sales 2025 |
3.2x | EV / Sales 2026 * | 2.41x |
| Free-Float |
67.55% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Iqvia Holdings Inc.
| 1 day | -1.13% | ||
| 1 week | -10.96% | ||
| Current month | -27.46% | ||
| 1 month | -30.89% | ||
| 3 months | -25.32% | ||
| 6 months | -12.24% | ||
| Current year | -25.94% |
| 1 week | 156.66 | 194.83 | |
| 1 month | 156.66 | 244.16 | |
| Current year | 156.66 | 247.04 | |
| 1 year | 134.64 | 247.04 | |
| 3 years | 134.64 | 261.73 | |
| 5 years | 134.64 | 285.61 | |
| 10 years | 60.23 | 285.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 65 | 03/10/2016 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 65 | 01/08/2020 |
Jeffrey Spaeder
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
John Leonard
BRD | Director/Board Member | 68 | 05/02/2015 |
John Connaughton
BRD | Director/Board Member | 60 | 01/01/2008 |
Ari Bousbib
CHM | Chairman | 65 | 03/10/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.13% | -10.96% | -14.85% | -28.08% | 28.31B | ||
| +4.62% | +0.73% | -12.88% | -4.40% | 47.61B | ||
| -0.10% | -2.22% | +53.47% | +41.20% | 38.3B | ||
| -0.21% | +8.18% | +39.13% | +61.33% | 36.11B | ||
| -1.05% | -1.21% | +133.08% | +277.09% | 18.62B | ||
| +7.58% | +14.65% | +33,042.25% | +4,133.79% | 15.44B | ||
| +2.25% | -3.74% | +29.62% | -3.02% | 13.72B | ||
| -0.82% | -2.62% | +51.81% | +89.94% | 13.28B | ||
| -1.44% | -6.82% | +165.57% | +103.18% | 13.06B | ||
| +2.88% | -21.03% | +25.01% | +87.04% | 12.15B | ||
| Average | +1.26% | -2.97% | +3,351.22% | +475.81% | 23.66B | |
| Weighted average by Cap. | +1.31% | -1.95% | +2,191.96% | +318.38% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 16.18B 13.64B 12.44B 11.87B 22.04B 1,466B 22.9B 145B 57.43B 708B 60.69B 59.44B 2,474B | 17.22B 14.51B 13.23B 12.63B 23.45B 1,560B 24.37B 154B 61.1B 753B 64.57B 63.25B 2,632B |
| Net income | 1.23B 1.04B 946M 903M 1.68B 111B 1.74B 11B 4.37B 53.81B 4.61B 4.52B 188B | 1.44B 1.22B 1.11B 1.06B 1.97B 131B 2.04B 12.9B 5.12B 63.13B 5.41B 5.3B 221B |
| Net Debt | 13.35B 11.25B 10.26B 9.79B 18.18B 1,209B 18.89B 119B 47.36B 584B 50.05B 49.02B 2,040B | 13.21B 11.13B 10.15B 9.69B 17.99B 1,196B 18.69B 118B 46.87B 578B 49.53B 48.51B 2,019B |
Employees
93,000
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 166.94 $ | -1.13% | 4,265,627 |
| 12/02/26 | 168.85 $ | -4.70% | 7,055,519 |
| 11/02/26 | 177.18 $ | -2.89% | 4,558,876 |
| 10/02/26 | 182.45 $ | -5.30% | 3,647,315 |
| 09/02/26 | 192.67 $ | +2.76% | 2,045,149 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
24
Last Close Price
166.94USD
Average target price
246.10USD
Spread / Average Target
+47.42%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IQV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition

















